secwatch.observer — SEC 8-K summary
======================================

Issuer:     ATAI Life Sciences N.V. (—)
CIK:        0001840904
Form:       8-K
Filed at:   2024-05-15T23:59:59+00:00
Accession:  0001140361-24-026094
Event type: leadership
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CEO Florian Brand to step down by YE2024; Dr. Rao to succeed; Q1 net loss $26.7M
--------------------------------------------------------------------------------

- CEO Florian Brand to step down by Dec 31, 2024; will serve as Co-CEO from June 1 until then.
- Co-Founder Dr. Srinivas Rao appointed Co-CEO effective June 1, 2024; to become CEO by YE2024.
- Q1 2024 net loss $26.7M ($33.1M in Q1 2023); R&D expenses $11.5M, down from $19.3M YoY.
- Cash, equivalents and short-term investments $121.3M at March 31, 2024; sufficient into 2026.
- VLS-01 Phase 1b data and BPL-003 Phase 2b TRD topline data both expected in 2H 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840904/000114036124026094/0001140361-24-026094-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840904/000114036124026094/ef20029167_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-026094

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer